|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,650.00 JPY | +3.57% |
|
+5.99% | -16.28% |
| 13/04 | Cosmos Pharmaceutical's Nine-Month Profit Rises 1.8% | MT |
| 13/04 | Cosmos Pharmaceutical Corporation Provides Consolidated Earnings Guidance for the Full Year of Fiscal Year Ending May 31, 2026 | CI |
Company Valuation: COSMOS Pharmaceutical Corporation
Data adjusted to current consolidation scope
| Fiscal Period: May | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 6,03,094 | 4,83,107 | 5,25,081 | 5,02,890 | 7,00,001 | 5,27,061 | - | - |
| Change | - | -19.9% | 8.69% | -4.23% | 39.2% | -24.71% | - | - |
| Enterprise Value (EV) 1 | 5,53,560 | 4,50,132 | 4,97,354 | 4,77,918 | 6,92,920 | 5,08,852 | 4,95,227 | 4,87,267 |
| Change | - | -18.68% | 10.49% | -3.91% | 44.99% | -26.56% | -2.68% | -1.61% |
| P/E | 22.2x | 20.9x | 22.1x | 20.6x | 22.6x | 15.9x | 15.4x | 14.5x |
| PBR | 3.54x | 2.54x | 2.49x | 2.17x | 2.72x | 1.79x | 1.64x | 1.5x |
| PEG | - | -1.4x | 7.98x | 7.61x | 0.8x | 5.29x | 4.06x | 2.58x |
| Capitalization / Revenue | 0.83x | 0.64x | 0.63x | 0.52x | 0.69x | 0.48x | 0.45x | 0.42x |
| EV / Revenue | 0.76x | 0.6x | 0.6x | 0.5x | 0.69x | 0.46x | 0.42x | 0.39x |
| EV / EBITDA | 11.8x | 10x | 10.5x | 9.29x | 11.1x | 7.67x | 7.04x | 6.54x |
| EV / EBIT | 16.7x | 15.1x | 16.5x | 15.2x | 17.1x | 12.1x | 11.3x | 10.5x |
| EV / FCF | 65.2x | -39.1x | 93.5x | -222x | -807x | 117x | 74.7x | 61.1x |
| FCF Yield | 1.53% | -2.56% | 1.07% | -0.45% | -0.12% | 0.85% | 1.34% | 1.64% |
| Dividend per Share 2 | 35 | 40 | 50 | 60 | 70 | 76.07 | 82.21 | 88.7 |
| Rate of return | 0.46% | 0.66% | 0.75% | 0.95% | 0.79% | 1.18% | 1.28% | 1.38% |
| EPS 2 | 342.9 | 292.4 | 300.5 | 308.6 | 390.9 | 402.6 | 417.9 | 441.3 |
| Distribution rate | 10.2% | 13.7% | 16.6% | 19.4% | 17.9% | 18.9% | 19.7% | 20.1% |
| Net sales 1 | 7,26,424 | 7,55,414 | 8,27,697 | 9,64,989 | 10,11,390 | 10,95,360 | 11,78,422 | 12,58,448 |
| EBITDA 1 | 46,932 | 44,906 | 47,496 | 51,425 | 62,633 | 66,374 | 70,301 | 74,540 |
| EBIT 1 | 33,147 | 29,796 | 30,128 | 31,501 | 40,404 | 42,066 | 43,856 | 46,214 |
| Net income 1 | 27,156 | 23,155 | 23,797 | 24,454 | 30,978 | 31,908 | 33,122 | 34,984 |
| Net Debt 1 | -49,534 | -32,975 | -27,727 | -24,972 | -7,081 | -18,209 | -31,834 | -39,794 |
| Reference price 2 | 7,615.00 | 6,100.00 | 6,630.00 | 6,345.00 | 8,832.00 | 6,421.00 | 6,421.00 | 6,421.00 |
| Nbr of stocks (in thousands) | 79,198 | 79,198 | 79,198 | 79,258 | 79,257 | 79,257 | - | - |
| Announcement Date | 12/07/21 | 11/07/22 | 10/07/23 | 12/07/24 | 11/07/25 | - | - | - |
1JPY in Million2JPY
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 15.95x | 0.45x | 7.39x | 1.18% | 315.55Cr | |
| 22.3x | 0.35x | 5.72x | 2.28% | 599.27Cr | |
| 17.13x | 0.46x | 6.55x | 1.2% | 353.35Cr | |
| 13.24x | 0.46x | 5.82x | 3.55% | 277.08Cr | |
| 19.75x | 0.75x | 10.58x | 1.53% | 220.1Cr | |
| 13.47x | 0.4x | 3.82x | 3.76% | 128.24Cr | |
| 17.12x | 0.5x | 6.82x | 4.17% | 36Cr | |
| Average | 16.99x | 0.48x | 6.67x | 2.52% | 275.65Cr | |
| Weighted average by Cap. | 18.04x | 0.45x | 6.61x | 2.13% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 3349 Stock
- Valuation COSMOS Pharmaceutical Corporation
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
